Misophonia
Conditions
Keywords
Misophonia, Transcranial Magnetic Stimulation, Crossover trial, Single session, EEG
Brief summary
The purpose of the project is to assess the efficacy of parietal transcranial magnetic stimulation in misophonia. N=60 participants will undergo two transcranial magnetic stimulation sessions: one inhibitory and another excitatory. During both sessions, the parietal region will be stimulated. Participants will perform computerized tasks immediately before and after the stimulation, while EEG, heart rate, and skin temperature will be recorded. These recordings will be used to assess if TMS can be used to improve tolerance to misophonia triggers.
Interventions
OTHERTranscranial Magnetic Stimulation (TMS)
Transcranial Magnetic Stimulation (TMS) is an FDA-approved non-invasive brain stimulation technology. It is currently used for treating depression. Applications to other disorders such as OCD and anxiety using TMS are currently under investigation. TMS will be administered for 25 minutes.
Sponsors
Icahn School of Medicine at Mount Sinai
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
This is a TMS study. Only the technician administering TMS will be unblinded. All parties will be blinded till the end of the study. The technician is not involved in the data analysis.
Intervention model description
Participants will undergo two sessions of TMS, one inhibitory and another excitatory. The immediate changes resulting from both will be measured and compared.
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* Hypersensitive to presence of a specific sound, which may be accompanied by irritation, anger/outbursts, or fear. * Must be between the ages of 18 - 55. * Must be fluent in English since the study's instructions, surveys, and tasks will be in English.
Exclusion criteria
* Epilepsy or previous episode of convulsion or seizure. * Previous episode of fainting spell or syncope. * Head trauma. * Hearing problems. * Cochlear implant. * Metal in the brain, skull, or anywhere else in the body (e.g., splinters, fragments, clips, etc.). * Implanted neurostimulator (e.g., DBS, epidural/subdural, VNS). * Presence of cardiac pacemaker or intracardiac lines. * Presence of medication infusion device. * Use of pro-convulsant or epileptogenic medications. * Pregnancy. The risks associated with TMS exposure during gestation have not been studied extensively. We wish to safeguard the health of potential participants and their children. * Lactation. The risks associated with TMS during lactation and its effects on infant development have not been studied. We wish to safeguard the health of potential participants and their children. * Presence of Mania, Psychosis, Antisocial Personality Disorder, Borderline Personality Disorder, and Suicidal Ideation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Unpleasantness Rating Scale | after each session, 72 hours apart (each session is 2 hours) | Participants will be presented with a slider with extremes labelled as extremely unpleasant and extremely pleasant. Ratings will be provided for audio clips and visual cues. Full scale from 0-100, higher score indicates more unpleasantness |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Heart Rate | after each session, 72 hours apart (each session is 2 hours) | The heart rate (number of beats per minute) will be measured using a wristwatch worn by the participant. |
| Skin Conductance Response | after each session, 72 hours apart (each session is 2 hours) | Skin conductance, a measure capturing the amount of sweat, will be measured using a wristwatch worn by the participant. |
| EEG P1-N1-P2 Complex Peak Amplitude | after each session, 72 hours apart (each session is 2 hours) | Amplitude (microvolts) of P1, N1, and P2 peaks measured in the parietal region |
| EEG P1-N1-P2 Complex Peak Latency | after each session, 72 hours apart (each session is 2 hours) | Latency (milliseconds) of P1, N1, and P2 peaks measured in the parietal region |
| EEG Frequency Band Amplitude | after each session, 72 hours apart (each session is 2 hours) | Amplitude (decibel) in theta (4-8 Hz), alpha (8-13 Hz), and beta (13-30 Hz) frequency bands in the parietal region |
| EEG Frequency Band Inter-Trial Coherence | after each session, 72 hours apart (each session is 2 hours) | Coherence (unitless) across trials in theta (4-8 Hz), alpha (8-13 Hz), and beta (13-30 Hz) frequency bands in the parietal region |
Countries
United States
Contacts
CONTACTShama Patel
CONTACTParul Jain, PhD
PRINCIPAL_INVESTIGATORParul Jain, PhD
Icahn School of Medicine at Mount Sinai
Outcome results
None listed